Skip to main content

Table 1 Disease transition rates

From: Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Transition

Mean

SE

Sources

F0 to F1

0.084

NA

[17]

F1 to F2

0.092

NA

F2 to F3

0.145

NA

F3 to F4

0.116

NA

F4 (compensated cirrhosis) to decompensated cirrhosis

0.039

0.010

[20]

F4 (compensated cirrhosis) to HCC

0.014

0.010

Decompensated cirrhosis to HCC

0.014

0.010

Decompensated cirrhosis to liver transplant

0.030

0.012

Decompensated cirrhosis to death

0.130

0.010

HCC to liver transplant

0.030

0.012

HCC to death

0.430

0.030

Liver transplant (year 1) to death

0.210

0.046

Liver transplant (year 2+) to death

0.057

0.012

  1. HCC hepatocellular carcinoma, NA not applicable, SE standard error